摘要
目的 对治疗复发/难治性多发性骨髓瘤患者(RRMM)使用达雷妥尤单抗的效果予以分析。方法 回顾性方式对2021年1月至2023年4月筛选的70例RRMM患者予以研究,依照用药方式的不同分组,参照组(n=35)给予硼替佐米+环磷酰胺+地塞米松方案(BCD方案),研究组(n=35)给予BCD方案+达雷妥尤单抗治疗,对比分析治疗缓解率、CD38浆细胞群阳性表达率及其Notch1表达水平与不良反应。结果 缓解率研究组高于参照组,差异有统计学意义(P <0.05);CD38阳性表达率研究组低于参照组,差异有统计学意义(P <0.05);治疗前CD38阳性浆细胞表面Notch1表达水平对比,差异无统计学意义(P> 0.05),治疗后研究组低于参照组,差异有统计学意义(P <0.05);两组血液系统、消化系统不良反应发生率对比差异无统计学意义(P> 0.05)。结论 在常规治疗基础上联合达雷妥尤单抗治疗,可提升RRMM患者总体缓解率,不会额外增加不良反应。
Objective To analyze the efficacy of daratumumab in the treatment of patients with relapsed/refractory multiple myeloma(RRMM).Methods A retrospective study was conducted on 70 RRMM patients selected from January 2021 to April 2023.The patients were divided into two groups according to different treatment regimens:the control group(n=35) received bortezomib+cyclophosphamide+dexamethasone(BCD regimen),and the study group(n=35) received BCD regimen plus daratumumab treatment.The therapeutic response rate,CD38-positive plasma cell expression rate,Notch1 expression level,and adverse reactions were compared between the two groups.Results The remission rate in the study group was higher than that in the control group,with statistically significant differences(P < 0.05);the CD38-positive expression rate in the study group was lower than that in the control group,with statistically significant differences(P < 0.05);there was no statistically significant difference in CD38-positive plasma cell surface Notch1 expression level before treatment between the two groups(P > 0.05),but after treatment,the study group was lower than the control group,with statistically significant differences(P < 0.05);there was no statistically significant difference in the incidence of adverse reactions in the hematologic and digestive systems between the two groups(P > 0.05).Conclusion The combination of daratumumab with conventional treatment can improve the overall remission rate of RRMM patients without additional adverse reactions.
作者
苗宁宁
MIAO Ningning(Affiliated Department of Hematology,Puyang Oilfield General Hospital,Puyang Henan 457000,China)
出处
《临床研究》
2024年第5期103-105,共3页
Clinical Research
